GSK share price today: why the stock dipped after China approved Nucala for COPD

GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease. The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT. Investing

LSE:GSK · Pharmaceuticals · Stock Market
London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

That timing matters, because the LSE is heading into a classic “thin liquidity” stretch: fewer traders at their desks, wider bid–ask spreads, and price moves that can look louder than the underlying news. The next London session is set to reopen at 8:00 a.m. London time on Monday, December 29, according to the exchange’s own market status display. London Stock Exchange
27 December 2025
···
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

December 26, 2025 — GSK plc stock is closing out the year with a familiar mix of “defensive pharma stability” and “pipeline-driven volatility.” The past two weeks delivered a cluster of headline-worthy updates: a U.S. FDA approval for GSK’s twice-yearly asthma biologic, a high-profile U.S. drug-pricing agreement that directly touches GSK’s respiratory franchise, regulatory momentum for expanded vaccine use in Europe, and fresh competitive noise around Shingrix—one of GSK’s biggest profit engines.
26 December 2025
···
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

London | Friday, 26 December 2025 — The UK stock market is effectively on pause today, with the London Stock Exchange closed for the Boxing Day bank holiday. But “no trading” doesn’t mean “no market story”: investors are spending the day digesting a strong 2025 run for the FTSE 100, fresh signals from the make-or-break retail season, and a global backdrop dominated by a year-end risk rally and a fresh spike in precious metals that could ripple through London-listed miners when UK dealing resumes. Reuters
26 December 2025
·····
UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

London — 25 December 2025. UK investors heading into Friday, 26 December 2025 should start with one practical reality: there is no standard London cash equity session tomorrow. From there, attention shifts to what’s been moving the FTSE 100, the pound, commodities and rate expectations into year-end — and what could matter most when trading resumes.
25 December 2025
····
United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

London — Thursday, 25 December 2025. The United Kingdom stock market is closed today for Christmas Day, putting a temporary pause on trading after a holiday-shortened run into the break. With the London Stock Exchange also shut on Friday for Boxing Day, the next meaningful read on UK risk appetite will come when markets reopen after the long weekend. MoneyWeek
25 December 2025
····
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in Europe, and a steady drumbeat of buybacks. For investors tracking GSK stock, the headline isn’t just one event—it’s the way policy, pipeline, and capital returns are colliding in the same two-week window.
20 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK plc is ending 2025 with a busy headline tape—exactly the kind of environment where investors tend to re-check both the “story” and the spreadsheet. On Thursday, December 18, 2025, GSK published a fresh share buyback update, while markets continue to digest a string of regulatory milestones across respiratory, vaccines, and infectious diseases that could shape the company’s growth profile into 2026.
18 December 2025
··
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK plc stock is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice a year. The approval lands as the company approaches a leadership handover on Jan. 1, 2026, and as investors weigh whether GSK’s late‑2025 pipeline momentum can translate into durable earnings growth in 2026 and beyond. Reuters+2GSK+2
17 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc stock is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps.
15 December 2025
··
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK plc heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion for an antibiotic, and steady buyback activity. That combination doesn’t guarantee a breakout, but it does give investors a clearer map of what could move GSK shares in the days ahead.
14 December 2025
···
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

GSK plc is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3
13 December 2025
··
1 2 3 4
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.